-
BTN LiveBIG速8加速器vqn-outline
If there was a way to catch Alzheimer's earlier, to see its onset in the most nascent of stages, medical researchers postulate that would allow patients to access novel treatments earlier than ever before. At the University of Minnesota's Center for Drug Design (CDD), researchers are working towards that goal. First, however, the must surmount the problem of early detection. Read the article by John Tolley (and watch the video): Here
-
Photo by Brady Willette速8加速器vqn-outline
Finding a viable treatment for Alzheimer’s disease (AD) continues to frustrate researchers around the world. The University of Minnesota Center for Drug Design’s Robert Vince, PhD, and Swati More, PhD, aren’t exempt.
Vince, More, and their colleagues are developing a drug to treat early AD, but they wanted a faster way to test whether their compound was working. So they created a cost-effective, noninvasive eye-scanning technology to do the job, and their breakthrough is commanding international attention. Read the full story by Barbara Knox: Click Here -
速8加速器vqn-outline
The University of Minnesota Twin Cities and Windgap Medical have received a $3.2 million grant from the National Institutes of Health (NIH) to develop a new device to quickly administer a recently developed antidote for cyanide poisoning. Read More
-
速8加速器vqn-outline
NBC/KARE11 News: How an eye scan could catch Alzheimer's early
Watch the video by Heidi Wigdahl: Click Here
速8加速器vqn-outline
速8加速器vqn-outline
The Center for Drug Design (CDD) was created to combine research and scholarship leading to the development of novel drugs for therapeutic applications, such as HIV, cancer, neurological diseases, dermatological agents, infectious diseases, novel processes, and medical devices. The Center for Drug Design combines the best of academic tradition along with an expectation of innovation and independence, and provides significant value for our academic and research community.
Read the full message